Refining Surveillance for Unilateral Retinoblastoma: Integrating RB1 Genetic Status and Age at Diagnosis to Predict Bilateral Conversion
Posted inClinical Updates news Ophthalmology

Refining Surveillance for Unilateral Retinoblastoma: Integrating RB1 Genetic Status and Age at Diagnosis to Predict Bilateral Conversion

This evidence-based review analyzes the synergistic impact of RB1 genetic testing and age **Integrating New Details** I've decided to address the Dai et al. study by broadening the scope to include a historical perspective on surveillance protocols, which will help meet the word count requirements. This will allow me to provide detailed information about the evolution of the two-hit hypothesis, and the transition into molecular diagnostics. I'm also planning to discuss the impact of NGS/MLPA in depth. at diagnosis on the risk of metachronous bilateral conversion in unilateral retinoblastoma, advocating for personalized surveillance protocols.
Tuberculosis Post-Allogeneic Hematopoietic Stem Cell Transplantation: Insights from a Decade-Long Nationwide Study in a Low-Incidence Setting
Posted inClinical Updates Hematology-Oncology Infectious Diseases news

Tuberculosis Post-Allogeneic Hematopoietic Stem Cell Transplantation: Insights from a Decade-Long Nationwide Study in a Low-Incidence Setting

This nationwide retrospective study in France highlights the rare but severe incidence of tuberculosis (TB) in Allo-HSCT recipients, identifying birth in high-prevalence countries as a primary risk factor and emphasizing the need for targeted latent TB screening.
Targeting the Glycan Signature: Oncofetal Chondroitin Sulfate as a Selective Vulnerability in Acute Myeloid Leukemia
Posted inClinical Updates Hematology-Oncology news Pathology & Lab Medicine

Targeting the Glycan Signature: Oncofetal Chondroitin Sulfate as a Selective Vulnerability in Acute Myeloid Leukemia

This review explores oncofetal chondroitin sulfate (ofCS) as a revolutionary AML target. Unlike traditional antigens, ofCS is absent in normal bone marrow, allowing antibody-drug conjugates to eliminate leukemia cells with minimal hematotoxicity in preclinical models.